These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 39095849)

  • 1. The molecular prognostic score, a classifier for risk stratification of high-grade serous ovarian cancer.
    Sarkar S; Saha SA; Swarnakar A; Chakrabarty A; Dey A; Sarkar P; Banerjee S; Mitra P
    J Ovarian Res; 2024 Aug; 17(1):159. PubMed ID: 39095849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
    Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
    Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
    Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
    Hillman RT; Chisholm GB; Lu KH; Futreal PA
    J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
    Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
    EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
    Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
    Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.
    Wu M; Sun Y; Wu J; Liu G
    Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
    Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
    Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma.
    Yuan D; Zhu H; Wang T; Zhang Y; Zheng X; Qu Y
    Eur J Med Res; 2023 Oct; 28(1):465. PubMed ID: 37884970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
    Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
    Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
    Zhang Y; Liu J; Raj-Kumar PK; Sturtz LA; Praveen-Kumar A; Yang HH; Lee MP; Fantacone-Campbell JL; Hooke JA; Kovatich AJ; Shriver CD; Hu H
    Breast Cancer Res Treat; 2020 Dec; 184(3):689-698. PubMed ID: 32880016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic gene expression signature for high-grade serous ovarian cancer.
    Millstein J; Budden T; Goode EL; Anglesio MS; Talhouk A; Intermaggio MP; Leong HS; Chen S; Elatre W; Gilks B; Nazeran T; Volchek M; Bentley RC; Wang C; Chiu DS; Kommoss S; Leung SCY; Senz J; Lum A; Chow V; Sudderuddin H; Mackenzie R; George J; ; Fereday S; Hendley J; Traficante N; Steed H; Koziak JM; Köbel M; McNeish IA; Goranova T; Ennis D; Macintyre G; Silva De Silva D; Ramón Y Cajal T; García-Donas J; Hernando Polo S; Rodriguez GC; Cushing-Haugen KL; Harris HR; Greene CS; Zelaya RA; Behrens S; Fortner RT; Sinn P; Herpel E; Lester J; Lubiński J; Oszurek O; Tołoczko A; Cybulski C; Menkiszak J; Pearce CL; Pike MC; Tseng C; Alsop J; Rhenius V; Song H; Jimenez-Linan M; Piskorz AM; Gentry-Maharaj A; Karpinskyj C; Widschwendter M; Singh N; Kennedy CJ; Sharma R; Harnett PR; Gao B; Johnatty SE; Sayer R; Boros J; Winham SJ; Keeney GL; Kaufmann SH; Larson MC; Luk H; Hernandez BY; Thompson PJ; Wilkens LR; Carney ME; Trabert B; Lissowska J; Brinton L; Sherman ME; Bodelon C; Hinsley S; Lewsley LA; Glasspool R; Banerjee SN; Stronach EA; Haluska P; Ray-Coquard I; Mahner S; Winterhoff B; Slamon D; Levine DA; Kelemen LE; Benitez J; Chang-Claude J; Gronwald J; Wu AH; Menon U; Goodman MT; Schildkraut JM; Wentzensen N; Brown R; Berchuck A; Chenevix-Trench G; deFazio A; Gayther SA; García MJ; Henderson MJ; Rossing MA; Beeghly-Fadiel A; Fasching PA; Orsulic S; Karlan BY; Konecny GE; Huntsman DG; Bowtell DD; Brenton JD; Doherty JA; Pharoah PDP; Ramus SJ
    Ann Oncol; 2020 Sep; 31(9):1240-1250. PubMed ID: 32473302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers.
    Li Y; Fei H; Lin Q; Liang F; You Y; Li M; Wu M; Qu Y; Li P; Yuan Y; Chen T; Jiang H
    Oncogene; 2021 Aug; 40(32):5131-5141. PubMed ID: 34211089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
    Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
    Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.
    Guan J; Darb-Esfahani S; Richter R; Taube ET; Ruscito I; Mahner S; Woelber L; Prieske K; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1063-1073. PubMed ID: 30810838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.
    Tassi RA; Gambino A; Ardighieri L; Bignotti E; Todeschini P; Romani C; Zanotti L; Bugatti M; Borella F; Katsaros D; Tognon G; Sartori E; Odicino F; Romualdi C; Ravaggi A
    Br J Cancer; 2019 Oct; 121(7):584-592. PubMed ID: 31434988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.